Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report
Sign Up to like & getrecommendations! Published in 2017 at "Cardiology"
DOI: 10.1159/000455089
Abstract: Tafamidis meglumine is a novel medicine that has been shown to slow the progression of peripheral neurological impairment in patients with hereditary transthyretin amyloidosis (ATTR). However, the efficacy of tafamidis against ATTR-related cardiac amyloidosis remains… read more here.
Keywords: tafamidis treatment; amyloid cardiomyopathy; treatment; case ... See more keywords
Unwanted road to anaemia in transthyretin familial amyloid polyneuropathy may continue irrespective of tafamidis treatment
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Clinical Biochemistry"
DOI: 10.1177/0004563218754587
Abstract: Background This retrospective longitudinal study was performed to determine whether tafamidis treatment leads to improvements in commonly used blood data for transthyretin familial amyloid polyneuropathy (TTR-FAP). Methods Commonly used blood data (complete blood count [including… read more here.
Keywords: tafamidis treatment; treatment; ttr; blood ... See more keywords